Drug intelligence / Profile preview

RPTR-1-005

Development stage: Preclinical
Lead developer: Repertoire Immune Medicines
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

RPTR-1-005 is a preclinical-stage, tumor antigen-specific bispecific T-cell receptor (TCR) engaging molecule being developed by Repertoire Immune Medicines for the treatment of multiple solid tumors. Discovered using Repertoire's proprietary DECODE platform, which maps the immune synapse to identify TCR-epitope pairs, RPTR-1-005 is designed to redirect and activate a patient's own T cells to target and destroy tumor cells. The therapeutic candidate is administered parenterally and is currently undergoing preclinical evaluation.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on RPTR-1-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPTR-1-005.

Explore the full profile